free web stats

Law Offices of Thomas J. Lamb

Ozempic Eye Side Effect NAION Warnings Update July 2026

By

Non-arteritic anterior ischemic optic neuropathy (NAION) is an eye side effect associated with Ozempic in numerous medical reports over the past couple of years. This article provides an Ozempic eye side effect NAION warnings update as of late July 2026 covering the US and some other countries around the world.

On July 23, 2026, the Australian drug regulatory agency Therapeutic Goods Administration (TGA) issued a Medicines Safety Update titled “GLP-1 RAs and rare vision disorder”,  which pointed out that the Ozempic eye side NAION warnings would be added in Australia.

Further, in that July 2026 TGA Medicines Safety Update where the Ozempic NAION risk is highlighted, one finds a list of earlier actions taken by some other international drug regulators:

However, the current (Revised: 5/2026 version) Ozempic Prescribing Information, or drug label, in the United States still does not include warnings about Ozempic-related eye side effects, such as NAION.

Drug injury lawsuits involving Ozempic for patients with vision loss due to NAION are being filed in the US against Novo Nordisk for its failure to include Ozempic eye side effect NAION warnings.

We emphasize that because there are no warnings in the current Ozempic drug label about an increased risk of NAION, those Ozempic lawsuits are not being filed against the doctors who prescribed Ozempic to the people who have suffered vision loss due to this serious eye-related side effect.

People diagnosed with NAION can submit an Ozempic Vision Loss Case Evaluation Form online. Or, if you prefer, call 910-256-2971 to talk with drug injury lawyer Tom Lamb about a possible Ozempic NAION lawsuit.

[Read the article in full at Drug Injury Watch]

Ozempic

Free Case Evaluation

Strictly Confidential, No Obligation

Semaglutide NAION Lawsuits in 2026 for Wegovy, Rybelsus, Ozempic Vision Loss

By

Semaglutide NAION lawsuits in 2026 are based on the failure to warn about this serious eye side effect. These court cases seek legal compensation for patients diagnosed with NAION vision loss or blindness.

In more detail, lawsuits for Wegovy, Rybelsus, and Ozempic vision loss cases involving semaglutide-associated nonarteritic anterior ischemic optic neuropathy (NAION) are filed against Novo Nordisk, the pharmaceutical company responsible for those three semaglutide-containing GLP-1 drugs. This is because, at present, there is no warning about semaglutide-associated NAION in the current drug labels for Ozempic, Rybelsus, and Wegovy.

Some new important evidence for these semaglutide NAION lawsuits involving Ozempic, Rybelsus, and Wegovy is found in this medical journal article published in May 2026 by PLOS Medicine, “Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies“.

From the Abstract for this recent PLOS Medicine medical journal article relevant to Wegovy, Rybelsus, and Ozempic NAION vision loss cases:

Conclusions: Our findings suggest a possible association between semaglutide use and an increased risk of NAION in patients with [type 2 diabetes (T2DM)]. Although the absolute risk is low, clinicians should be aware of this potential adverse event, particularly in individuals at increased baseline risk for optic neuropathies. While these findings support current recommendations to discontinue semaglutide in patients diagnosed with NAION, the certainty of the available evidence is low, underscoring the need for further high-quality studies to clarify this association.

However, as we pointed out above, the current drug labels for Ozempic, Wegovy, and Rybelsus do not have any warning about semaglutide-associated NAION vision loss or blindness as a possible side effect.

As seen by this list of earlier Drug Injury Law articles, our law firm is very familiar with the semaglutide-associated NAION side effects of Ozempic, Wegovy, and Rybelsus:

In addition, our law firm has experience handling semaglutide NAION lawsuits involving Wegovy, Rybelsus, and Ozempic vision loss or blindness cases for patients.

Patients diagnosed with NAION-related vision loss or blindness can submit an Ozempic/Wegovy/Rybelsus Vision Loss Case Evaluation Form online. Or, if you prefer, call 910-256-2971 to talk with drug injury lawyer Tom Lamb about semaglutide NAION lawsuits.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

NAION Linked To Zepbound, Mounjaro, Ozempic, Wegovy: 2026 News Update

By

The eye side effect non-arteritic anterior ischemic optic neuropathy (NAION) linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other glucagon-like peptide-1 receptor agonists (GLP-1RA) drugs is the focus of an April 2026 medical study report published online by JAMA Network Open.

This medical study report, “GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy“, presents a 2025 analysis of 2017 – 2023 health records from the US Department of Veterans Affairs (VA) done to investigate the rate of this NAION eye side effect that users of Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs have reported.

When all was said and done, the authors of this 2026 medical study report about NAION concluded:

In this large cohort study, [Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs] use was associated with a modestly increased risk of NAION compared with [sodium-glucose cotransporter-2 inhibitors (SGLT2i) drugs] use. While the absolute risk remains low, the specificity of this finding may warrant heightened vigilance.

NAION linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs is an issue that first came to light in the second part of 2024. For example, two large medical studies from Denmark found that people who used Ozempic had double the risk of developing NAION, which can cause vision loss and blindness.

Drug Injury Lawsuits for NAION Linked to Zepbound, Mounjaro, Ozempic, or Wegovy

In the past couple of years, NAION drug injury lawsuits involving Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs have been filed against the responsible pharmaceutical companies for their failure to warn patients and doctors about the risk of developing NAION.

For an introduction to the medical and legal aspects of these NAION drug injury lawsuits, here are two relevant Drug Injury Law website links:

We are investigating cases of NAION linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs for patients as drug injury lawsuits seeking legal compensation for their vision loss. We point out that those NAION lawsuits would not be filed against the patients’ doctors because the pharmaceutical company failed to warn about the NAION eye side effect associated with their drug.

[Read the article in full at Drug Injury Watch]

Mounjaro / Zepbound

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic /  Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Tavneos Label Change Adds Vanishing Bile Duct Syndrome (VBDS) Warnings

By

Just two days after the FDA announced it was considering a Tavneos drug recall, Amgen countered with a Tavneos label change that adds warnings for vanishing bile duct syndrome (VBDS).

As regards this April 2026 Tavneos label change adding more liver side effects, and specifically the new warning for Tavneos-related vanishing bile duct syndrome (VBDS), we get the following information from a May 1, 2026, EndpointNews report, “Amgen files update to Tavneos label as FDA escalates push to withdraw“:

Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA.

The company filed a supplement on Wednesday that would add more information to the warning label about post-market cases of vanishing bile duct syndrome (VBDS), a serious liver complication that can lead to death. The supplement, disclosed in Amgen’s first-quarter earnings release, marks another twist in the company’s ongoing saga with regulators over Tavneos’ future on the market….

The FDA asked Amgen to pull Tavneos from the market voluntarily at the beginning of this year.

[The FDA’s Center for Drug Evaluation and Research (CDER)] reiterated its push in a proposal to withdraw the drug earlier this week, citing new information that it says suggests Tavneos “has not shown to be effective for its approved use,” and that its marketing application held “untrue statements of material fact.” The FDA accused study personnel of manipulating the results of a pivotal clinical trial used to approve the drug.

Regulators also said they were “increasingly concerned” about the drug’s safety.

To understand the context in which Amgen proposed a Tavneos label change that adds vanishing bile duct syndrome warnings by means of its April 29, 2026, filing with the FDA, we point out this excerpt from this April 27, 2026, FDA Drug Alerts and Statements document, “CDER proposes to withdraw approval of TAVNEOS“:

Additionally, CDER is increasingly concerned about the safety profile of TAVNEOS. As further detailed in a March 31, 2026, drug safety communication, CDER has identified cases of serious drug-induced liver injury (DILI) associated with TAVNEOS. Some cases involved vanishing bile duct syndrome (VBDS), which is characterized by progressive destruction and disappearance of the bile ducts in the liver. Although hepatotoxicity is a serious adverse reaction for TAVNEOS identified in premarket clinical trials and described in product labeling, VBDS and DILI cases with fatal outcomes represent new safety concerns.

Here are two recent Drug Injury Watch articles relevant to the Tavneos label change that adds vanishing bile duct syndrome warnings, as well as the possible FDA Tavneos drug recall:

Even before this Tavneos label change that adds more liver side effects in April 2026, we have been investigating possible drug injury lawsuits involving patients diagnosed with Tavneos-related vanishing bile duct syndrome (VBDS) or Tavneos drug-induced liver injury (DILI).

If you or someone you know was diagnosed with the VBDS or DILI Tavneos liver side effects, you can submit a Drug Injury Case Evaluation Form online, email lawyer Tom Lamb at TJL@LambLawOffice.com, or call him at 910-256-2971.

Tavneos

Free Case Evaluation

Strictly Confidential, No Obligation

Tavneos Legal Cases: Drug Injury Law Information – Five (5) Points

By

We are investigating Tavneos legal cases for people who have developed the Tavneos side-effects of vanishing bile duct syndrome (VBDS) or drug-induced liver injury (DILI). In this post, we share some case criteria and drug injury law information, presenting factors relevant to a possible “new” Tavneos litigation involving personal injury and wrongful death claims.

Tavneos Legal Cases

As of this point in time, Tavneos legal cases alleging drug injury could be filed for a person diagnosed with vanishing bile duct syndrome (VBDS) or drug-induced liver injury (DILI). These are the two types of established Tavneos side-effects outlined in this March 2026 Drug Safety Communication, “FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan) for Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis“.

As regards vanishing bile duct syndrome (VBDS), a rather distinctive and singular medical condition, from that FDA Tavneos warning:

Some cases involved vanishing bile duct syndrome (VBDS), which is characterized by progressive destruction and disappearance of the bile ducts in the liver. This condition can slow or stop the flow of bile and may lead to permanent liver damage. VBDS is often accompanied by the yellowing of skin or eyes (jaundice), itchiness, and tiredness.

To provide some facts and guidance about a possible Tavenos-related drug-induced liver injury (DILI) — because that “umbrella” term touches upon various types of liver disease and therefore, is a more complex topic — we refer you to this “Drug-induced liver injury” page of the online Medical Encyclopedia on the MedlinePlus website, published by the US NIH National Library of Medicine.

Those Tavneos lawsuits will seek legal compensation from the responsible drug companies through a Complaint filed in a federal or state court as a drug injury lawsuit.

Drug Injury Law Information

The Complaint in a drug injury lawsuit for Tavenos-related liver damage, such as vanishing bile duct syndrome (VBDS) or drug-induced liver injury (DILI), would likely begin with setting the factual stage generally, then moving on to a set of standard liability allegations and contentions.

We provide the following five (5) points of drug injury law information in an attempt to give you some idea about what types of statements, typically, might be included in Tavneos legal cases with personal injury and wrongful death claims:

  1. It is not unusual for an FDA-approved drug that appeared effective and safe to later be found to be unsafe. One reason is that after a drug comes onto the market and is prescribed to a larger patient population, harmful patterns can emerge that were not fully understood during the smaller “pre-approval” clinical trials.
  2. If a drug is later found to be unsafe, it is possible that the particular drug side effect was not adequately disclosed, not adequately investigated, or not properly acted upon once drug-safety “signals”, or warning signs, emerged.
  3. In that setting, Tavneos legal cases may focus on whether drug label safety warnings were timely and strong enough, whether physician communications such as “Dear Doctor letters’ should have been issued, and whether the responsible drug companies gave enough weight to the liver injury drug-safety “signals”, or warning signs, that emerged since the FDA first approved Tavneos in October 2021.
  4. Moreover, the fact that there has been a “disagreement” between the FDA and the drug companies may be a factor in Tavneos legal cases. It could be expected that, where the FDA expressed concern that Tavneos liver injury side effects are serious enough to seek removal of Tavneos from the US market, the plaintiffs in these Tavneos legal cases may argue that the drug companies should have disclosed, investigated, or acted sooner to protect patients. (For details on this “disagreement”, see the last part of our 3/31/26 post, “Tavneos Liver Injury Drug Safety Communication Issued by FDA in Late March 2026 — Just 2 Months Earlier, Amgen Refused an FDA Request to Withdraw Tavneos; Will There Be a Tavneos Recall Soon?”)
  5. For the reasons above, injured patients may pursue legal compensation by means of drug injury lawsuits, which often focus on inadequate or missing safety warnings, delayed action or investigation in connection with drug-safety “signals”, and other conduct that shows a failure to fully protect patients from emerging or known serious side effects risks.

For people with possible Tavneos legal cases, you can submit a Drug Injury Case Evaluation Form online. It is free, confidential, and there is no obligation. You will get a reply from drug injury lawyer Tom Lamb no later than the next business day.

In the alternative and/or for more relevant drug injury law information, send an email to Tom Lamb at TJL@LambLawOffice.com, or call him at 910-256-2971.

Tavneos

Free Case Evaluation

Strictly Confidential, No Obligation

Tavneos FDA Warnings: Liver Side Effects, Death Cases

By

In March 2026, Tavneos FDA warnings about liver side effects and some death cases were issued, just a couple of months after the FDA had requested that Amgen recall Tavneos for drug safety reasons.

According to the FDA, Tavneos (avacopan) is used together with glucocorticoids and other standard-of-care medications to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis), a group of rare diseases that cause inflammation in small-to-medium-sized blood vessels.

Tavneos FDA Warnings

We get the following information from this March 31, 2026 Drug Safety Communication, “FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan) for Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis“:

FDA is alerting patients and health care professionals about serious postmarketing cases, including fatal cases, of drug-induced liver injury (DILI) associated with Tavneos (avacopan). Some cases involved vanishing bile duct syndrome (VBDS), which is characterized by progressive destruction and disappearance of the bile ducts in the liver.

///

Patients should contact their health care professional immediately if they develop any signs or symptoms that may indicate liver injury, such as: feeling more tired than usual; nausea; vomiting; unusual itching; light-colored stools; yellowing of skin or eyes; dark urine; swelling in the stomach or abdomen; or pain in the right upper abdomen.

As mentioned at the start, before these March 2026 Tavneos FDA warnings, the drug manufacturer Amgen rejected an FDA request in February 2026 for a Tavneos recall over concerns about drug-induced liver injury (DILI) and vanishing bile duct syndrome (VBDS) liver side effects, as well as reports made to the FDA about death cases involving Tavneos.

Now, a week after the March 31, 2026 Tavneos FDA warnings about these DILI and VBDS liver side effects, and even with those death cases involving Tavneos, there has been no indication from Amgen that there will be a Tavneos recall.

We are investigating possible personal injury lawsuits to be filed against Amgen on behalf of patients using Tavneos who developed serious liver side effects, including DILI and VBDS, or the families who may have wrongful death cases involving Tavneos to bring against Amgen, as the responsible drug company.

[Read the article in full at Drug Injury Watch]

Tavneos

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic and Wegovy NAION Study 2026 Report: Two New Findings

By

A recent Ozempic and Wegovy NAION study made two new findings about people who used Ozempic or Wegovy and then were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) as a drug side effect that caused vision loss. The first is that the Wegovy NAION rate is five times that of Ozempic. The second is that for users of Ozempic and Wegovy, NAION was diagnosed in men three times more than in women.

These findings from the Ozempic and Wegovy NAION study were presented in this March 2026 British Journal of Ophthalmology article, “Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk“.

News Articles About

Ozempic and Wegovy NAION Study

Here are three news articles that provide the details and some contextual information about the Ozempic and Wegovy NAION study 2026 report:

“Wegovy May Carry Highest Risk of Blinding Condition Among GLP-1 Drugs“, MedPage Today, 3/10/26

“Wegovy linked to higher risk of eye stroke and vision loss“, BMJ Group, 3/10/26

“Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds“, The Guardian, 3/10/26

We have been following the vision side-effect drug safety issue that is the subject of this Ozempic and Wegovy NAION study report since July 2024. During that time, we have investigated possible drug injury lawsuits against Novo Nordisk for patients diagnosed with NAION and who suffered vision loss.

Earlier Posts Related to

Ozempic and Wegovy NAION Study

Related to this Ozempic and Wegovy NAION study 2026 report, here is a list of some of our earlier posts about non-arteritic anterior ischemic optic neuropathy (NAION) associated with the semaglutide-containing drugs Wegovy and Ozempic, as well as Rybelsus, all from Novo Nordisk:

If you have a possible NAION drug injury lawsuit involving one of the semaglutide drugs from Novo Nordisk that you want reviewed, you can submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online, send an email to TJL@LambLawOffice.com, or call us at 910-256-2971.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version

By

We have written about the Ozempic-NAION side effect drug safety issue several times over the past year-and-a-half, and have repeatedly pointed out that NAION is linked to semaglutide, the active ingredient in the currently available Novo Nordisk semaglutide medicines: Ozempic injection, Wegovy injection, Wegovy tablet, and Rybelsus tablet. Further, we have suggested that all these Novo Nordisk semaglutide medicines should have NAION warnings, such that there would be Ozempic-NAION warnings, Wegovy-NAION warnings, and Wegovy-NAION warnings.

But as of late January 2026, when the “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” was released, none of the drug labels for Novo Nordisk semaglutide medicines included any NAION warnings.

Before providing some information about why we suggest Ozempic-NAION warnings should be in the recently released January 2026 drug label for the new tablet or pill version of Ozempic that will be available in the US later this year, we direct you to this February 4, 2026, Novo Nordisk USA announcement, “Novo Nordisk introduces Ozempic® Pill; Available in the US Q2 2026” for some information about that new drug product.

Ozempic-NAION Warnings Information

Here are two earlier articles from our Drug Injury Watch blog that provide support for this suggestion that there should be Ozempic-NAION warnings included in that January 2026 drug label for the new pill version of Ozempic, soon to be available, as well as the current drug label for the already available, and popular, Ozempic injection:

  1. “Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs”  (2/13/2026)
  2. “Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness”  (10/22/2025)

The failure by Novo Nordisk to have Ozempic-NAION warnings available for doctors who prescribe Ozempic — or Rybelsus, or Wegovy — as well as the people who use these popular Novo Nordisk semaglutide medicines is the basis for drug injury lawsuits that have been filed against this pharmaceutical company on behalf of people diagnosed with non-arteritic anterior ischemic optic neuropathy, or NAION.

If you have been diagnosed with NAION while using one of those Novo Nordisk semaglutide medicines or soon thereafter, you may want to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online. It is free, confidential, and there is no obligation.

In the alternative, if you have a possible Wegovy, Rybelsus, or Ozempic NAION drug injury lawsuit that you want evaluated by drug injury attorney Tom Lamb, you can send an email to TJL@LambLawOffice.com or call 910-256-2971.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs

By

The semaglutide-containing drug Ozempic has been linked to non-arteritic anterior ischemic optic neuropathy (NAION). A 2026 medical journal article reported that the Ozempic NAION risk 200% higher than that of some other diabetes drugs, such as Invokana (canagliflozin), Jardiance (empagliflozin), and Farxiga (dapagliflozin), which are sodium-glucose cotransporter-2 (SGLT2) inhibitors, also referred to as SGLT2i drugs. Like Ozempic, the SGLT2 inhibitors Invokana, Jardiance, and Farxiga are used to treat Type 2 diabetes.

This article, “New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes”, published in February 2026 by the medical journal JAMA Ophthalmology, begins with a “Key Points” part that includes the following:

Question Is semaglutide associated with an increased risk of incidence of nonarteritic anterior ischemic optic neuropathy (NAION) compared with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes?

Findings In this study, among a group of US veterans with type 2 diabetes, initiation of semaglutide was associated with a 2-fold higher risk of incident NAION compared with initiation of an SGLT2i,…

In addition to Ozempic, two other semaglutide-containing drugs are Wegovy and Rybelsus, so this new evidence about the Ozempic NAION risk applies to those drugs, also. We point out that Novo Nordisk is the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.

Ozempic NAION Risk: Earlier Posts

Here are some of the earlier posts relevant to this recently reported medical fact that the Ozempic NAION risk 200% higher than that of some other diabetes drugs:

The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about non-arteritic anterior ischemic optic neuropathy (NAION) as a possible eye-related side effect that can cause vision loss.

Given that situation, together with newly reported evidence of the Ozempic NAION risk 200% higher than that of some other diabetes drugs, we are handling drug injury lawsuits for patients who developed the NAION eye-related side effect associated with Ozempic, Wegovy, and Rybelsus.

Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients diagnosed with NAION would be filed against Novo Nordisk for its failure to warn about NAION as a possible side effect.

If you have a possible Rybelsus, Wegovy, or Ozempic NAION case that you would like to have investigated for a drug injury lawsuit, you can submit an online Case Evaluation Form. If you prefer, send attorney Tom Lamb an email (TJL@LambLawOffice.com) or call him (910-256-2971).

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Rybelsus Pancreatitis Warnings and Rybelsus Drug Injury Lawsuits

By

Rybelsus Pancreatitis Warnings

In October 2025, warnings about pancreatitis were added to the Rybelsus “drug label”. Insofar as there were no Rybelsus pancreatitis warnings until October 2025, there is a possible “failure to warn” products liability claim for people who were diagnosed with Rybelsus pancreatitis side effects before October 2025.

From the Rybelsus (semaglutide) tablets Prescribing Information “Revised: 10/2025” version [PDF document], here is the actual text for these new Rybelsus pancreatitis warnings:

5.2 Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS [see Adverse Reactions (6)]. After initiation of RYBELSUS, observe patients carefully for signs and symptoms of pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue RYBELSUS and initiate appropriate management.

Rybelsus Pancreatitis Drug Injury Lawsuits

We are investigating Rybelsus pancreatitis drug injury lawsuits, with a focus on cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death. Those Rybeslus pancreatitis death cases would be filed against the responsible pharmaceutical company, Novo Nordisk.

The best possible Rybelsus pancreatitis drug injury lawsuits would be for people who were diagnosed with pancreatitis before October 2025 because, as indicated above, those cases could include a “failure to warn” legal allegation against the drug company Novo Nordisk.

And cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death would be the most significant Rybelsus drug injury lawsuits in terms of legal compensation and liability, and better than those cases where the pancreatitis went away after a person stopped using Rybelsus.

Finally, cases involving acute pancreatitis diagnosed after October 2025 while using Rybelsus are less likely to be filed as drug injury lawsuits against Novo Nordisk due to the Rybelsus drug label change above that added the pancreatitis drug side-effect warnings.

If you have a possible Rybelsus pancreatitis drug injury lawsuit that you would like to have investigated by drug injury attorney Tom Lamb, you can submit an online Case Evaluation Form. If you prefer, send him an email (TJL@LambLawOffice.com) or call him (910-256-2971).

[Read the article in full at Drug Injury Watch]

Rybelsus

Free Case Evaluation

Strictly Confidential, No Obligation

Our Other Websites

DrugInjuryWatch.com

LambLawOffice.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971
TJL@LambLawOffice.com